VEGFA and hepatocellular carcinoma: Additionally, it has been found miR-199a/b-3p can inhibit HCC growth, apoptosis, invasion and angiogenesis via multiple targets, such as PDCD4, CD44, CD151, VEGFA AEGFR1/2, HGF and MMP235–38 and can affect the chemical sensitivity of hepatoma cells to doxorubicin via mTOR and c-Met39.